THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $345 | -51.0% | 40 | -41.2% | 0.00% | – |
| Q2 2023 | $704 | +70300.0% | 68 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | 0.0% | 68 | 0.0% | 0.00% | – |
| Q4 2022 | $1 | -99.9% | 68 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | -98.1% | 68 | -99.0% | 0.00% | – |
| Q3 2021 | $52,000 | -33.3% | 7,000 | +84.2% | 0.00% | – |
| Q1 2021 | $78,000 | +14.7% | 3,800 | 0.0% | 0.00% | – |
| Q4 2020 | $68,000 | +23.6% | 3,800 | +3.1% | 0.00% | – |
| Q3 2020 | $55,000 | +511.1% | 3,687 | +738.0% | 0.00% | – |
| Q2 2020 | $9,000 | -92.6% | 440 | -91.6% | 0.00% | -100.0% |
| Q1 2020 | $121,000 | -13.6% | 5,250 | -3.0% | 0.00% | 0.0% |
| Q4 2019 | $140,000 | -15.7% | 5,410 | -36.4% | 0.00% | 0.0% |
| Q3 2019 | $166,000 | -9.3% | 8,500 | -24.1% | 0.00% | -50.0% |
| Q2 2019 | $183,000 | -28.0% | 11,199 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $254,000 | – | 11,199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Madison Avenue Partners, LP | 7,012,226 | $60,515,510 | 8.59% |
| Irenic Capital Management LP | 2,760,948 | $23,826,981 | 6.76% |
| Newtyn Management, LLC | 1,841,560 | $15,892,663 | 3.92% |
| Weiss Asset Management LP | 7,457,060 | $64,354,428 | 3.81% |
| Park West Asset Management LLC | 1,983,251 | $17,115,456 | 1.57% |
| Baupost Group | 7,419,226 | $64,028 | 1.23% |
| Oasis Management Co Ltd. | 953,254 | $8,226,582 | 0.36% |
| Chescapmanager LLC | 287,333 | $2,479,684 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 325,985 | $2,813 | 0.24% |
| Virtus ETF Advisers LLC | 29,232 | $252,272 | 0.15% |